Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate: preliminary aggregate results from three phase 1a randomized, double-blind, placebo controlled clinical trials

BACKGROUND: The expansion of Zika virus (ZIKV) into the Western Hemisphere and recognition of congenital Zika syndrome have created a need for a safe, effective and rapidly-scalable ZIKV vaccine. We developed a purified formalin-inactivated ZIKV vaccine (ZPIV) candidate that was advanced to human te...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet
Main Authors: Modjarrad, Kayvon, Lin, Leyi, George, Sarah L, Stephenson, Kathryn E, Eckels, Kenneth H, De La Barrera, Rafael A, Jarman, Richard G, Sondergaard, Erica, Tennant, Janice, Ansel, Jessica, Mills, Kristin, Koren, Michael, Robb, Merlin L, Barrett, Jill, Thompson, Jason, Kosel, Alison E, Dawson, Peter, Hale, Andrew, Tan, C Sabrina, Walsh, Stephen, Meyer, Keith E, Brien, James, Crowell, Trevor A, Blazevic, Azra, Mosby, Karla, Larocca, Rafael A, Abbink, Peter, Boyd, Michael, Bricault, Christine A, Seaman, Michael, Basil, Anne, Walsh, Melissa, Tonwe, Veronica, Hoft, Daniel F, Thomas, Stephen J, Barouch, Dan H, Michael, Nelson L
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5884730/
https://ncbi.nlm.nih.gov/pubmed/29217375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(17)33106-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados